Clinical Trial Update: Study of Epcoritamab as a Consolidation Therapy in CLL/SLL [Phase 2]

View source ↗

Summary

Phase 2 study evaluating epcoritamab as consolidation therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)

Snippet

Sponsor: Zulfa Omer | Conditions: CLL/SLL, CLL | Phase 2 | Status: RECRUITING